Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Ltd. announced a proposed issue of 164,300,000 ordinary fully paid securities, scheduled for issuance on May 26, 2025. This strategic move is expected to enhance the company’s capital structure, potentially strengthening its position in the biotechnology sector and providing additional resources for its ongoing research and development efforts.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is dedicated to advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies to address unmet medical needs in oncology.
Technical Sentiment Signal: Sell
Current Market Cap: A$14.81M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue